BGC > Produktsuche > Fevipiprant | 872365-14-5

Molecular Formula: C19H17F3N2O4S

Description:
Fevipipran is a reversible competitive CRTh2 antagonist with IC50 value of 0.44 nM for inhibition of PGD2-induced eosinophil shape change in human whole blood. Now it is in Phase III clinical trials for the treatment of asthma.

• Molecular Weight:426.41
• Purity:98%

Molecular Formula:
C19H17F3N2O4S
Canonical SMILES:
CS(C1=CC=C(CN2C(C)=C(CC(O)=O)C3=C2N=CC=C3)C(C(F)(F)F)=C1)(=O)=O
InChI:
InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)
InChIKey:
GFPPXZDRVCSVNR-UHFFFAOYSA-N
Solubility:
Soluble in DMSO
Appearance:
Powder
Application:
Allergic asthma; Atopic dermatitis
Storage: -20℃ Freezer
Synonyms:
NVP-QAW039; NVP-QAW 039; NVP-QAW-039 QAW-039; QAW039; QAW 039; Fevipiprant; 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid